当前位置:
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.
The Lancet Respiratory Medicine ( IF 76.2 ) Pub Date : 2021-09-01 , DOI: 10.1016/s2213-2600(21)00358-1 Andre C Kalil 1 , Justin Stebbing 2
中文翻译:
Baricitinib:第一个在安慰剂对照试验中降低 COVID-19 死亡率的免疫调节治疗。
更新日期:2021-08-31
The Lancet Respiratory Medicine ( IF 76.2 ) Pub Date : 2021-09-01 , DOI: 10.1016/s2213-2600(21)00358-1 Andre C Kalil 1 , Justin Stebbing 2
Affiliation
中文翻译:
Baricitinib:第一个在安慰剂对照试验中降低 COVID-19 死亡率的免疫调节治疗。